Tyche Industries Ltd
Incorporated in 1998, Tyche Industries Ltd
does manufacturing of active pharmaceutical ingredients[1]
- Market Cap ₹ 172 Cr.
- Current Price ₹ 167
- High / Low ₹ 230 / 149
- Stock P/E 12.6
- Book Value ₹ 130
- Dividend Yield 1.49 %
- ROCE 13.7 %
- ROE 10.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 5.20% over past five years.
- Company has a low return on equity of 10.9% over last 3 years.
- Earnings include an other income of Rs.5.76 Cr.
- Dividend payout has been low at 12.5% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
78 | 104 | 64 | 54 | 43 | 52 | 54 | 74 | 78 | 62 | 75 | 70 | 72 | |
68 | 94 | 57 | 51 | 37 | 43 | 45 | 52 | 54 | 51 | 59 | 57 | 58 | |
Operating Profit | 10 | 11 | 7 | 3 | 6 | 9 | 9 | 21 | 25 | 11 | 16 | 13 | 14 |
OPM % | 13% | 10% | 11% | 5% | 14% | 18% | 17% | 29% | 32% | 18% | 21% | 18% | 19% |
1 | 0 | 0 | 2 | 2 | 2 | 3 | 4 | 4 | 3 | 5 | 6 | 6 | |
Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Profit before tax | 9 | 8 | 3 | 3 | 6 | 9 | 10 | 23 | 27 | 13 | 19 | 17 | 18 |
Tax % | 33% | 32% | 33% | 4% | 48% | 34% | 27% | 25% | 25% | 26% | 26% | 26% | |
6 | 6 | 2 | 2 | 3 | 6 | 7 | 18 | 20 | 9 | 14 | 12 | 13 | |
EPS in Rs | 5.94 | 5.39 | 1.88 | 2.41 | 3.00 | 5.72 | 6.98 | 17.13 | 19.49 | 9.10 | 13.82 | 11.94 | 12.79 |
Dividend Payout % | 8% | 9% | 26% | 21% | 17% | 9% | 7% | 0% | 5% | 16% | 0% | 21% |
Compounded Sales Growth | |
---|---|
10 Years: | -4% |
5 Years: | 5% |
3 Years: | -4% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 11% |
3 Years: | -16% |
TTM: | -7% |
Stock Price CAGR | |
---|---|
10 Years: | 22% |
5 Years: | 13% |
3 Years: | -2% |
1 Year: | -8% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 15% |
3 Years: | 11% |
Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 28 | 33 | 34 | 35 | 38 | 43 | 50 | 67 | 86 | 94 | 107 | 116 | 123 |
11 | 11 | 9 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
39 | 19 | 12 | 11 | 13 | 14 | 14 | 18 | 21 | 16 | 20 | 10 | 15 | |
Total Liabilities | 88 | 74 | 64 | 67 | 61 | 67 | 74 | 95 | 117 | 120 | 137 | 137 | 148 |
28 | 33 | 29 | 28 | 27 | 20 | 19 | 18 | 18 | 17 | 17 | 18 | 17 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
60 | 40 | 35 | 39 | 34 | 47 | 55 | 77 | 98 | 104 | 120 | 119 | 131 | |
Total Assets | 88 | 74 | 64 | 67 | 61 | 67 | 74 | 95 | 117 | 120 | 137 | 137 | 148 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | 9 | 2 | 12 | 11 | 5 | 4 | 15 | 15 | 4 | 6 | 8 | |
-6 | -6 | -1 | -1 | 1 | 6 | 1 | 2 | 0 | 3 | -3 | 4 | |
2 | 0 | -3 | 2 | -11 | -1 | -0 | -1 | -1 | -1 | -2 | -2 | |
Net Cash Flow | -1 | 3 | -2 | 12 | 1 | 11 | 4 | 17 | 15 | 7 | 2 | 10 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 149 | 46 | 91 | 107 | 81 | 68 | 69 | 64 | 80 | 96 | 107 | 100 |
Inventory Days | 168 | 91 | 138 | 68 | 84 | 85 | 123 | 122 | 148 | 148 | 195 | 157 |
Days Payable | 265 | 68 | 76 | 93 | 130 | 87 | 96 | 91 | 93 | 78 | 134 | 48 |
Cash Conversion Cycle | 52 | 69 | 153 | 82 | 34 | 67 | 96 | 94 | 135 | 167 | 168 | 210 |
Working Capital Days | 100 | 68 | 122 | 89 | 60 | 67 | 87 | 77 | 83 | 121 | 129 | 144 |
ROCE % | 22% | 18% | 7% | 5% | 12% | 18% | 17% | 34% | 32% | 13% | 17% | 14% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Jan - Confirmation of no dematerialization requests for shares.
-
Updates
8 Jan - USFDA issued 'Official Action Indicated' after inspection.
- Closure of Trading Window 24 Dec
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov 2024 - Newspaper Publication of Financial Results for the 2nd Quarter and Half Year ended September 30, 2024
-
Board Meeting Outcome for Board Meeting Outcome For Approval Of Un-Audited Financial Results For The 2Nd Quarter & Half Year Ended 30Th September 2024
13 Nov 2024 - Board approved unaudited financial results for Q2 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Company is a manufacturer and exporter of APIs, Intermediates and Nutraceuticals. It is one of the largest Indian manufacturers of Glucosamine Hydrochloride and corresponding sodium and potassium salts which are mainly exported to USA and Europe